Patents by Inventor XiaoLan Zheng

XiaoLan Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220009901
    Abstract: The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine.
    Type: Application
    Filed: June 22, 2021
    Publication date: January 13, 2022
    Inventors: JEFFREY WALLACE JOHANNES, SUDHIR MAHADEO HANDE, AVIPSA GHOSH, XIAOLAN ZHENG, MARTIN PACKER, SEBASTIEN LOUIS DEGORCE
  • Patent number: 11149024
    Abstract: Disclosed are intermediates and methods of synthesizing Compound 1.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 19, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Craig Robert Stewart, Simon Hardy, Andrew Stark, Alexander Hird, Qing Ye, Xiaolan Zheng, Cati Ferrar, Jan Koek, Debasis Hazra
  • Publication number: 20210230184
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Application
    Filed: December 4, 2020
    Publication date: July 29, 2021
    Applicant: AstraZeneca AB
    Inventors: Alexander HIRD, Matthew BELMONTE, Wenzhan YANG, Paul SECRIST, Daniel ROBBINS, Steven KAZMIRSKI, Dedong WU, Bo PENG, Jeffrey JOHANNES, Michelle LAMB, Qing YE, XiaoLan ZHENG
  • Publication number: 20210122735
    Abstract: Disclosed are intermediates and methods of synthesizing Compound 1.
    Type: Application
    Filed: March 29, 2018
    Publication date: April 29, 2021
    Applicant: ASTRAZENECA AB
    Inventors: Craig Robert STEWART, Simon HARDY, Andrew STARK, Alexander HIRD, Qing YE, Xiaolan ZHENG, Cati FERRAR, Jan KOEK, Debasis HAZRA
  • Patent number: 10889594
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15,016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: January 12, 2021
    Assignee: AstraZeneca AB
    Inventors: Alexander Hird, Wenzhan Yang, Daniel Robbins, Steven Kazmirski, Dedong Wu, Bo Peng, Jeffrey Johannes, Michelle Lamb, Qing Ye, Xiaolan Zheng
  • Publication number: 20190185485
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15,016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Application
    Filed: December 18, 2018
    Publication date: June 20, 2019
    Inventors: Alexander HIRD, Matthew BELMONTE, Wenzhan YANG, Paul SECRIST, Daniel ROBBINS, Steven KAZMIRSKI, Dedong WU, Bo PENG, Jeffrey JOHANNES, Michelle LAMB, Qing YE, Xiaolan ZHENG
  • Patent number: 10196404
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: February 5, 2019
    Assignee: AstraZeneca AB
    Inventors: Alexander Hird, Matthew Belmonte, Wenzhan Yang, Paul Secrist, Daniel Robbins, Steven Kazmirski, Dedong Wu, Bo Peng, Jeffrey Johannes, Michelle Lamb, Qing Ye, Xiaolan Zheng
  • Publication number: 20180155362
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Application
    Filed: October 23, 2017
    Publication date: June 7, 2018
    Applicant: AstraZeneca AB
    Inventors: Alexander HIRD, Matthew BELMONTE, Wenzhan YANG, Paul SECRIST, Daniel ROBBINS, Steven KAZMIRSKI, Dedong WU, Bo PENG, Jeffrey JOHANNES, Michelle LAMB, Qing YE, Xiaolan ZHENG
  • Publication number: 20150051185
    Abstract: The invention relates to chemical compounds of formula I, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.
    Type: Application
    Filed: July 24, 2014
    Publication date: February 19, 2015
    Applicant: AstraZeneca AB
    Inventors: Leslie DAKIN, James Edward DOWLING, Michelle Laurae LAMB, Jon READ, Qibin SU, XiaoLan ZHENG
  • Patent number: 8901307
    Abstract: The invention relates to chemical compounds of formula (I), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: December 2, 2014
    Assignee: AstraZeneca AB
    Inventors: Leslie Dakin, James Edward Dowling, Michelle Lamb, Jon Read, Xiaolan Zheng
  • Publication number: 20110218182
    Abstract: The invention relates to chemical compounds of formula (I), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.
    Type: Application
    Filed: July 2, 2009
    Publication date: September 8, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Leslie Dakin, James Edward Dowling, Michelle Lamb, Jon Read, Qibin Su, Xiaolan Zheng
  • Publication number: 20110098283
    Abstract: The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: May 17, 2010
    Publication date: April 28, 2011
    Inventors: Leslie Dakin, Claude Afona Ogoe, David Scott, XiaoLan Zheng
  • Publication number: 20100311748
    Abstract: The present disclosure relates to heterocyclic amide compounds, which are useful for inhibiting the Hedgehog pathway, and their use in treating a disease or medical condition mediated alone or in part by Hedgehog pathway inhibition. Also disclosed are methods for manufacture of these compounds, pharmaceutical compositions including these compounds, and use of these compounds in the manufacture of medicaments for treating such diseases and medical conditions in a subject. Formula (IA) with the provisio that either R2 or R3 is (Z).
    Type: Application
    Filed: August 29, 2008
    Publication date: December 9, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Leslie Dakin, Benjamin Fauber, Alexander Hird, James Janetka, Daniel John Russell, Qibin Su, Bin Yang, Xiaolan Zheng
  • Patent number: 7723337
    Abstract: The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: May 25, 2010
    Assignee: AstraZeneca AB
    Inventors: Leslie Dakin, Claude Afona Ogoe, David Scott, XiaoLan Zheng
  • Publication number: 20090270450
    Abstract: The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: May 5, 2009
    Publication date: October 29, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Leslie Dakin, Kevin Daly, David Del Valle, Thomas Gero, Claude Afona Ogoe, David Scott, Xiaolan Zheng
  • Publication number: 20090118261
    Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: August 26, 2005
    Publication date: May 7, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Leslie Dakin, Jayachandran Ezhuthachan, Stephen Lee, Paul Lyne, Timothy Pontz, XiaoLan Zheng
  • Publication number: 20090099210
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: December 22, 2008
    Publication date: April 16, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Michael Howard Block, Audrey Davies, Jayachandran Ezhuthachan, Sandra Ann Filla, Timothy Pontz, Daniel John Russell, Maria-Elena Theoclitou, XiaoLan Zheng
  • Patent number: 7498333
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: March 3, 2009
    Assignee: AstraZeneca AB
    Inventors: Brian Aquila, Michael Howard Block, Audrey Davies, Jayachandran Ezhuthachan, Sandra Ann Filla, Timothy Pontz, Daniel John Russell, Maria-Elena Theoclitou, XiaoLan Zheng
  • Publication number: 20090054411
    Abstract: The invention relates to chemical compounds of formula IA or IB: or pharmaceutically acceptable salts thereof which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: October 13, 2008
    Publication date: February 26, 2009
    Applicant: AstraZeneca AB
    Inventors: Donald Cook, Leslie Dakin, David Del Valle, Thomas Gero, David Scott, Xiaolan Zheng
  • Publication number: 20090012084
    Abstract: The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: September 15, 2008
    Publication date: January 8, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Leslie Dakin, Claude Afona Ogoe, David Scott, XiaoLan Zheng